Subscribe To
FUSN / Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
FUSN News
By Zacks Investment Research
August 8, 2023
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates
Fusion Pharmaceuticals Inc. (FUSN) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.39. This comp more_horizontal
By PRNewsWire
May 9, 2023
Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
HAMILTON, ON and BOSTON , May 9, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on develo more_horizontal
By PRNewsWire
March 2, 2023
Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
HAMILTON, ON and BOSTON , March 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on devel more_horizontal
By PRNewsWire
February 13, 2023
Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
HAMILTON, ON and BOSTON , Feb. 13, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on devel more_horizontal
By PRNewsWire
May 11, 2022
Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day
HAMILTON, ON and BOSTON, May 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on devel more_horizontal